Cargando…
Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment
The discovery of the oncometabolite 2-hydroxyglutarate in isocitrate dehydrogenase 1–mutated (IDH1-mutated) tumor entities affirmed the role of metabolism in cancer. However, large databases with tissue metabolites that are modulated by IDH1 mutation remain an area of development. Here, we present a...
Autores principales: | Trautwein, Christoph, Zizmare, Laimdota, Mäurer, Irina, Bender, Benjamin, Bayer, Björn, Ernemann, Ulrike, Tatagiba, Marcos, Grau, Stefan J., Pichler, Bernd J., Skardelly, Marco, Tabatabai, Ghazaleh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855807/ https://www.ncbi.nlm.nih.gov/pubmed/34941573 http://dx.doi.org/10.1172/jci.insight.153526 |
Ejemplares similares
-
Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes
por: Brendle, Cornelia, et al.
Publicado: (2020) -
Correction to: Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes
por: Brendle, Cornelia, et al.
Publicado: (2021) -
Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes
por: Richter, Vivien, et al.
Publicado: (2021) -
ATRX immunostaining predicts IDH and H3F3A status in gliomas
por: Ebrahimi, Azadeh, et al.
Publicado: (2016) -
GLINT: GlucoCEST in neoplastic tumors at 3 T—clinical results of GlucoCEST in gliomas
por: Bender, Benjamin, et al.
Publicado: (2021)